Exploring sensitivity to replicative stress in BRCA deficient Triple Negative Breast Cancer

Abstract

In Triple Negative Breast Cancer (TNBC), chemotherapy is the only systemic treatment and sustained remissions are rare. We propose to widen therapeutic options. About 30% TNBC tumors are BRCA1 deficient, presentoing defective DNA repair and increased sensitivity to genotoxic drugs. We hypothesized that BRCA-deficient TNBC are highly sensitive to replication stress inducing drugs, thus, opening new therapeutic perspectives. Our preliminary results shown that BRCA1-deficient TNBC cell lines and a CRISPR/Cas9 BRCA1 KO isogenic model display increased sensitivity to gemcitabine. Cell cycle distribution of gemcitabine treated BRCA1-deficient cells were characterized by an elevated Sub-G1 fraction caused by increased numbers of cells in replication catastrophe. This was illustrated by 80% of BRCA1-deficient cells showing persistent (48-72h post treatment) gH2AX staining in absence of RPA32 co-staining, whereas in the isogenic BRCA1 WT model gH2AX and RPA32 positive cell numbers started decreasing at 24h. Interestingly, we noted that in addition to replication catastrophe, BRCA-deficient cells treated with gemcitabine underwent aberrant mitosis as shown by a clear increase of micro-nuclei. Interestingly, in vivo experiments appear to reproduce in vitro data. Indeed, a BRCA hyper methylated TNBC PDX, showed a higher sensitivity to gemcitabine than the BRCA1 WT. In conclusion, our data suggest that BRCA-deficient tumors are more sensitive to the replication poison Gemcitabine. Furthermore, this sensitivity seems to be mediated by an accentuated replicative stress response that is not well managed. Upon gemcitabine treatment, the cells undergo important DNA damage that leads to stalled replication forks, and DNA breakage. In the absence of BRCA1, the HR pathway is compromised, which leads to fork collapse and accumulation of single stranded DNA, therefore exhausting the pool of RPA within the cell and inducing Replicative catastrophe. In addition to deficient replication gemcitabine treated BRCA-deficient, but not BRCA-proficient cells, are subjected to mitotic catastrophe.